Stock Market Reviews

Read and share opinions on CLDX (Celldex Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mark

Latest News

• Celldex: Q3 Earnings Snapshot
  Nov 10, 2025
• Celldex Therapeutics (CLDX): Evaluating Valuation After Recent Share Price Weakness
  Nov 10, 2025
• Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
  Nov 10, 2025
• Celldex to Present at Upcoming Investor Conferences
  Nov 7, 2025
• Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
  Nov 6, 2025
• Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
  Oct 30, 2025
• Celldex Therapeutics (CLDX): Evaluating Valuation After Barclays' Underweight Rating and Industry Concerns
  Oct 23, 2025
• Barclays Initiates Coverage of Celldex Therapeutics (CLDX) With an Underweight Rating
  Oct 21, 2025
• Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
  Oct 10, 2025
• Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
  Sep 17, 2025
• Celldex Therapeutics (CLDX) Reports Promising Phase 2 Study Results For Barzolvolimab
  Sep 10, 2025
• Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
  Sep 9, 2025
• LifeSci Capital Maintains a Buy on Celldex Therapeutics (CLDX), Keeps the PT
  Aug 20, 2025
• Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
  Aug 19, 2025
• Celldex Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
  Aug 10, 2025